Tioga Pharmaceuticals Receives $10,000,000 Series B Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=aa8b6dac-7641-44d3-b371-a2e8ff9da5d1&Preview=1 -
Date
4/12/2012 -
Company Name
Tioga Pharmaceuticals -
Mailing Address
9393 Towne Centre Dr. San Diego, CA 92121 -
Company Description
Tioga Pharmaceuticals is engaged in the development of novel therapies for the treatment of gastrointestinal diseases. Tioga is developing asimadoline, a proprietary small molecule, for treating irritable bowel syndrome (IBS) and post operative ileus. -
Website
http://www.tiogapharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$10,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Tioga is currently conducting a Phase 3 trial of its compound, asimadoline, for the treatment of diarrhea-predominant irritable bowel syndrome (D-IBS) under a special protocol assessment with the U.S. Food and Drug Administration (FDA). -
M&A Terms
-
Venture Investor
Thomas, McNerny & Partners -
Venture Investor
Genesys Capital
